Medical Health Cluster


Questions Remain About What SARS-CoV-2 Variants Should Go Into the Annual COVID-19 Vaccines Proposed by the FDA

From the beginning, a scorecard might have come in handy for keeping track of the whos, whats, and whens of COVID-19 vaccination. Both available messenger RNA (mRNA) vaccines and the Novavax protein subunit vaccine require a 2-dose primary series, but the interval between the 2 shots is a minimum of […]

Read More

Novavax Hopes Its COVID Shot Wins Over FDA, Vaccine Holdouts

 Americans may soon get a new COVID-19 vaccine option — shots made with a more tried-and-true technology than today’s versions. The big question: Why should they care? After long delays, the Food and Drug Administration is expected to decide within weeks whether to authorize Novavax’s vaccine. It’s late in the […]

Read More

Novavax COVID Jab Approved by MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) has today given conditional marketing authorisation (CMA) to Nuvaxovid, a COVID-19 vaccine developed by Novavax. It becomes the fifth COVID jab to which the MHRA has given regulatory approval. In the UK phase 3 trial, with over 15,000 participants, overall efficacy was […]

Read More

Novavax inicia el reclutamiento de la vacuna combinada COVID-NanoFlu Combination Vaccine

La compañía de biotecnología norteamericana Novavax ha anunciado mediante nota de prensa que ha comenzado el reclutamiento de voluntarios para la fase I/II del ensayo clínico de su vacuna combinada frente a la COVID-19, NVX-CoV2373, y gripe estacional, NanoFlu, que incluye el adyuvante Matrix-M (COVID-NanoFlu Combination Vaccine), al objeto de evaluar su […]

Read More